Skip to content
          • Log In
      Drug Discovery World (DDW)Drug Discovery World (DDW)
        • About Us
        • Subscribe Free
        • Media Info
        • Contact Us
          Drug Discovery World (DDW) Menu   ≡ ╳
          • Home
          • News
          • Exclusive Content
            • Features
            • Opinion
            • Market Reports
            • Trends & Analysis
            • Start-up Zone
          • DDW eBooks & eReports
          • Cancer Research
          • Business
          • Regulatory
          • Events
          • Webinars
          • Resources
          • Archive
            • –
              • 2000 Archive
              • 2001 Archive
              • 2002 Archive
              • 2003 Archive
              • 2004 Archive
              • 2005 Archive
              • 2006 Archive
            • –
              • 2007 Archive
              • 2008 Archive
              • 2009 Archive
              • 2010 Archive
              • 2011 Archive
              • 2012 Archive
              • 2013 Archive
            • –
              • 2014 Archive
              • 2015 Archive
              • 2016 Archive
              • 2017 Archive
              • 2018 Archive
              • 2019 Archive
          • Multimedia
            • Videos
            • Podcasts

          Sidebar Banner 6

          Sidebar Banner 7

          Sidebar Banner 8

          Sidebar Banner 12

          Sidebar Banner 18

          Sidebar Banner 19

          Sidebar Banner 20

          Sidebar Banner 21

        Gastroenterology

        Crohn's disease

        Eli Lilly’s ulcerative colitis drug approved in Great Britain

        4 July 2023

        The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to Eli Lilly’s mirikizumab for moderately to severely active ulcerative colitis. The drug is approved in adult patients who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment. “Ulcerative colitis is […]

        4D pharma new data for treatment of irritable bowel syndrome

        25 May 2021

        4D pharma has released additional positive data from its completed Phase II trial of LBP Blautix in subjects with irritable bowel syndrome with constipation (IBS-C) or with diarrhoea (IBS-D). The data has been presented in a poster session at Digestive Disease Week (DDW), on May 22, 2021, by Professor Eamonn Quigley, Head of Gastroenterology and […]

        Sidebar Banner 1

        Sidebar Banner 2

        Sidebar Banner 3

        Sidebar Banner 4

        Sidebar Banner 9

        Sidebar Banner 10

        Sidebar Banner 11

        Sidebar Banner 13

        Sidebar Banner 14

        Sidebar Banner 15

        Sidebar Banner 16

        Sidebar Banner 17

          • Contact Us
          • About Us
          • Subscribe FREE
          • Media Info
          • Log In
          • Terms and Conditions
          • Privacy Policy
          • Cookie Policy

        Follow our social accounts

             

        Copyright 2023 © Drug Discovery World (DDW). All Rights Reserved

        Designed & Developed with ❤ for digital by Inbound FinTech

        • Home
        • News
        • Exclusive Content
          • Features
          • Market Reports
          • Opinion
          • Trends & Analysis
          • Start-up Zone
        • DDW eBooks & eReports
        • Cancer Research
        • Business
        • Regulatory
        • Events
        • Webinars
        • Resources
        • Archive
        • Multimedia
          • Podcasts
          • Videos
        • About Us
        • Subscribe Free
        • Media Info
        • Contact Us
            • Log In